HEALTH

CRC risk may be highest among men with Type 2 diabetes, study finds

BY Allison Cerra

NEW YORK There may be a link between Type 2 diabetes and colorectal cancer among men, according to a new study published in Gastroenterology.

In a final study of 73,312 men and 81,663 women — which were participants selected from the prospective study "Cancer Prevention Study II Nutrition Cohort" — 1,567 men (227 with Type 2 diabetes) and 1,242 women (108 with Type 2 diabetes) were diagnosed with colon or rectal cancer by 2007. Among men, Type 2 diabetes was associated with increased risk of incident CRC compared with not having Type 2 diabetes. CRC risk was higher for those participants with Type 2 diabetes regardless of whether or not they used insulin.

 

Among women, Type 2 diabetes and insulin use were not associated with CRC risk, the authors said, which may support recent observations that the association may be more prominent in men than in women, and raise the possibility of a stronger association among individuals with a family history of CRC. The authors speculated that the lack of an association between Type 2 diabetes and CRC risk among women might relate to improved glucose control among women with Type 2 diabetes in recent years.

 

 

"While our study supports an association of Type 2 diabetes with colorectal cancer incidence among men, our results also suggested that insulin use is associated with a slight, but not a substantially increased, risk of colorectal cancer among men with Type 2 diabetes," said Peter Campbell of the American Cancer Society and lead author of this study. "Prevention strategies should emphasize adherence to guidelines intended for the general population, such as smoking cessation, weight management, exercise and regular early detection exams."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Mission Skincare gets MLB endorsement for muscle rub analgesic

BY Michael Johnsen

NEW YORK Mission Skincare on Monday announced a new licensing agreement with Major Leagure Baseball Properties around its external analgesic Mission maximum-strength muscle rub.

“The muscle rub market has lacked innovation for some time now, and we decided it was time to ‘change the game’ — again,” stated Mission president Josh Shaw. “Everything from the Arnica extract to the vanishing-scent menthol, and the roll-on ‘no-mess’ applicator to the travel-friendly-sized tube was deliberately designed for athletes and people who lead active lifestyles.”

 

“I’m excited to see this come together, especially since I’m an integral part of both organizations,” stated David Wright, New York Mets third baseman and one of the professional athlete co-founders of Mission. “Just like stretching after competition or even a workout, caring for muscles is essential to staying in shape and getting in the game to perform the next day.”

 

 

Added Howard Smith, SVP licensing at MLB, “Giving our players a recovery product is important. Our relationship with Mission will give our players additional tools to help protect them as they play, and support them as they recover to prepare for the next game.”

 

Mission’s new rub is available at Dick’s Sporting Goods, GNC and CVS/pharmacy.

 

In addition to Wright, Mission was founded in 2008 by professional athletes, including tennis great Serena Williams, Phoenix Suns’ Steve Nash, soccer phenom Mia Hamm, Olympic swimmer Amanda Beard and golfer Sergio Garcia.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Botox approved for migraines

BY Alaric DeArment

SILVER SPRING, Md. A popular beauty treatment has won approval as a medical treatment as well.

 

The Food and Drug Administration announced Friday the approval of Allergan’s Botox (onabotulinumtoxinA) for preventing headaches in adult patients with chronic migraine.

 

 

“Chronic migraine is one of the most disabling forms of headache,” FDA division of neurology products director Russell Katz said. “Patients with chronic migraine experience a headache more than 14 days of the month. This condition can greatly affect family, work and social life, so it’s important to have a variety of effective treatments available.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

D.CALABRESE says:
Sep-02-2013 09:43 pm

Can you please share what are the chemicals or ingredients used with this botox treatment? Surely they have included something on it that will help cure and prevent chronic migraine. Also, please include what are the suggested ages for a person to have this treatment. I’d also ask my friend from colleyville botox about it. Wish to get the important information from this treatment.

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?